Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine induction followed by allogeneic stem cell transplantation or continued azacitidine in high-risk myelodysplastic syndromes
2010-019673-15Phase 2Completed
- Sponsor
- Università Cattolica del Sacro Cuore
- Start
- Jul 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of azacitidine in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) (2 arms), sponsored by Università Cattolica del Sacro Cuore. Primary endpoint: Rate of enrolled patients suitable for bone marrow transplantation and actually undergoing transplantation after azacitidine. Started Jul 2010; status: completed.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on 2010-019673-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019673-15.